Therapeutic potential of adenosine kinase inhibitors

Bibliography

• WILLIAMS M: Adenosine: the prototypical modulator. Neurochem. Int. (1989) 14:249–264.
   PubMed Web of Science ®Google Scholar
• NEWBY AC: Adenosine and the concept of 'retaliatory metabolites'. Trends Biochem. Sci. (1984) 2:42–44.
   Web of Science ®Google Scholar
• RALEVIC V, BURNSTOCK G: Receptors for purines and pyrimidines. Pharmacol. Rev. (1998) 50:413–492.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of the pharmacology andphysiology of ADO and ATP.
   Google Scholar
• WILLIAMS M, BURNSTOCK G: Purinergic neurotrans- mission and neuromodulation: A historical perspec-tive. In: Purinergic Approaches in Experimental Therapeutics. Jacobson KA, Jarvis MF (Eds.), Wiley-Liss, New York, USA (1997):3–26.
   Google Scholar
• •A recent review providing a historical perspective of the area of purinergic transmission, P1 receptor classification and nomenclature and selective P1 receptor ligands.
   Google Scholar
• MOSER GH, SCHRADER J, DUESSEN A: Turnover ofadenosine in plasma of human and dog blood. Am. J. Physiol. (1989) 25:C799–C806.
   Google Scholar
• ARCH JRS, NEWSHOLME EA: The control of the metabo-lism and the hormonal role of adenosine. Essays Biochem. (1978) 14:82–123.
   PubMedGoogle Scholar
• DAVIES LP, JAMIESON DD, BAIRD-LAMBERT JA,KAZLAUSKAS R: Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: pharmacological activities and potent inhibition of adenosine kinase. Biochem. Pharmacol. (1984) 33:347–355.
   PubMed Web of Science ®Google Scholar
• •Isolation and characterisation of the potent AK inhibitor, 5'd–51T.
   Google Scholar
• NEWBY AC, HOLMQUIST AC, ILLINGWORTH J, PEARSONJD: The control of adenosine concentration in polymorphonuclear leukocytes, cultured cells and isolated perfused heart from the rat. Biochem. J. (1983) 214:317–323.
   PubMed Web of Science ®Google Scholar
• ENGLER RL: Consequences of activation and adenosinemediated inhibition of granulocytes during myocar-dial ischemia. Fed. Proc. (1987) 46:2407–2412.
   PubMedGoogle Scholar
• MULLANE K, YOUNG M: Acadesine: prototype adenosine regulating agent for treating myocardial ischemia-reperfusion injury. Drug Dev. Res. (1993) 23:336–343.
   Web of Science ®Google Scholar
• PAK MA, HAAS HL, DECKING UKM, SCHRADER J: Inhibi-tion of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacol. (1 9 9 4) 33:1049-1053.
   Google Scholar
• GOLEMBIOWSKA K, WHITE TD, SAWYNOK J: Adenosine kinase inhibitors augument release of adenosine from spinal cord slices. Eur.J. Pharmacol (1996) 307:157–162.
   PubMed Web of Science ®Google Scholar
• BRITTON DR, MIKUSA J, LEE CH, JARVIS MF, WILLIAMS M, KOWALUK EA: Site and event specific increase of striatal adenosine release by adenosine kinase inhibi-tion in rats. Neurosci. Lett. (1999) 266:93–96.
   PubMed Web of Science ®Google Scholar
• JARVIS MF, WILLIAMS M: Purinergic Approaches mechanisms in nervous system function and disease states. In: Psychopharmacology: 46 Generation of Progress CD-ROM Bloom FE, Kupfer DJ (Eds) Raven, New York, USA (1999) (In Press).
   Google Scholar
• •Detailed review of the purinergic cascade in CNS function. CD-ROM version contains multimedia presentations and links to relevant sites.
   Google Scholar
• STILES G: Adenosine receptor subtypes: New insightsfrom cloning and functional studies. In: Purinergic Approaches in Experimental Therapeutics. Jacobson KA, Jarvis MF, (Eds.). Wiley-Liss, New York, USA (1997):29–39.
   Google Scholar
• MAENHAUT C, VAN SANDE J, LIBERT F et al.: RDC8 codesfor an adenosine Ay receptor with physiological constitutive activity. Biochem. Biophys. Res. Comm. (1990) 173:1169–1178.
   PubMed Web of Science ®Google Scholar
• RIVKEES SA, REPPERT SM: RFL9 encodes an A2B adenosine receptor. Mol. Endocrinol (1992) 6:1598–1604.
   PubMed Web of Science ®Google Scholar
• BRUNS RF, LU GH, PUGSLEY TA: Characterization of the A2 adenosine receptor labeled by [311]NECA in rat striatal membranes. Mol. Pharmacol (1986) 29:331–346.
   PubMed Web of Science ®Google Scholar
• JARVIS MF: Characterization of P1 (adenosine) purino-ceptors. In: Current Protocols in Pharmacology. Enna S, Williams M (Eds), Wiley-Liss, New York, USA (1998):19.1-19.15.
   Google Scholar
• •Contains a detailed review of radioligand binding method-ologies for the A1, A2A and A3 receptors.
   Google Scholar
• LINDEN J: Cloned adenosine A3 receptors: pharmacol- ogical properties, species differences and receptor functions. Trends Pharmacol. Sci. (1994) 15:298–306.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B. ROMAGNOLI R, SPALLUTO G: At and A3 adenosine receptor agonists: an overview. Exp. Opin. Ther. Patents. (1999) 9:515–527.
   Web of Science ®Google Scholar
• ANDRES CM, FOX IH: Purification and properties of human placental adenosine kinase. J. Biol. Chem. (1979) 254:11388–11393.
   PubMed Web of Science ®Google Scholar
• DATTA AK, BHAUMIK D, CHATTERJEE R: Isolation andcharacterization of adenosine kinase from Leishmania donovani. J. Biol. Chem. (1 9 8 7) 262:5515-5521.
   Google Scholar
• GEIGER JD, PARKINSON FE, KOWALUK EA: Regulators of endogenous adenosine levels as therapeutic agents. In: Purinergic Approaches in Experimental Therapeutics. Jacobson KA, Jarvis MF (Eds). Wiley-Liss, New York, USA (1997) 55–84.
   Google Scholar
• PALELLA TD, ANDRES CM, FOX IH: Human placental adenosine kinase, kinetic mechanism and inhibition. J. Biol. Chem. (1980) 255:5264–5269.
   PubMed Web of Science ®Google Scholar
• MILLER RL, ADAMCZYK DL, MILLER WH et al.: Adenosine kinase from rabbit liver, II. Substrate and inhibitor specificity. J. Biol. Chem. (1979) 254:2346–2352.
   Web of Science ®Google Scholar
• KOWALUK EA, COWART M: Purification and characteri-zation of adenosine kinase from rat brain. Drug Dev. Res. (1994) 31:287.
   Google Scholar
• YAMADA Y, GOTO H, OGASAWARA N: Purification andproperties of adenosine kinase from rat brain. Biochem. Biophys. Acta (1980) 616:199–207.
   PubMed Web of Science ®Google Scholar
• HAWKINS CF, BAGNARA AS: Adenosine kinase from human erthrocytes: kinetic studies and characteriza-tion of adenosine binding sites. Biochem. (1987) 26:1982–1987.
   PubMed Web of Science ®Google Scholar
• LIN BB, HURLEY MC, FOX IH: Regulation of adenosinekinase by adenosine analogues. Mol Pharmacol (1988) 34:501–505.
   PubMed Web of Science ®Google Scholar
• ELALAOUI A, DIVITA G, MAURY G, IMBACH JL, GOODY RD: Intrinsic tryptophan fluorescence of bovine liver adenosine kinase, characterization of ligand binding sites and conformational changes. Eur. J. Biochem. (1994) 221:839–846.
   PubMedGoogle Scholar
• MCNALLY T, HELFRICH R, COWART M et al.: Cloning and expression of the adenosine kinase gene from rat and human tissues. Biochem. Biophys. Res. Comm. (1997) 231:645–650.
   PubMed Web of Science ®Google Scholar
• SPYCHALA J, DATTA NS, TAKABAYASHI K et al.: Cloningof human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases. Proc. Nat1 Acad. Sci. USA (1996) 93:1232–1237.
   Google Scholar
• MATTHEWS IL, ERION MD, EALICK SE: Structure of human adenosine kinase at 1.5A resolution. Biochem. (1998) 10:15607–15620.
   Web of Science ®Google Scholar
• BENNETT LL, HILL DL: Structural requirements for activity of nucleosides as substrates for adenosine kinase: orientation of substituents on the pentafura-nosyl ring. Mol. Pharmacol. (1975) 11:803–808.
   PubMed Web of Science ®Google Scholar
• MILLER RL, ADAMCZYK DL, MILLER WH et al.: Adenosine kinase from rabbit liver. I. Purification by affinity chromatography and properties. J. Biol. Chem. (1979) 254:2339–2345.
   PubMed Web of Science ®Google Scholar
• BENNET LL, ALLAN PW, HILL DL: Metabolic studies withcarbocyclic analogues of purine nucleosides. Mol. Pharmacol. (1968) 4:208–217.
   PubMed Web of Science ®Google Scholar
• ILTSCH MH, UBER SS, TANKERSLEY KO, EL KOUNI MH:Structure-activity relationship for the binding of nucleoside ligands to adenosine kinase from Toxoplasma Gondii. Biochem. Pharmacol. (1995) 49:1501–1512.
   PubMed Web of Science ®Google Scholar
• HENDERSON JF, PATERSON APP, CALDWELL IC, PAUL C,CHAN MC, LAU KF: Inhibition of nucleoside and nucleo-tide metabolism. Cancer Chemother. Rep. (1972) 3:71–85.
   Google Scholar
• COOK AF, HOLMAN MJ: Synthesis of the natural product 5'-deoxy-5-iodotubercidin and related halogenated analogues. Nucleosides Nucleotides (1984) 3:401–411.
   Web of Science ®Google Scholar
• FIRESTEIN GJ, BULLOUGH DA, ERION MD et al.: Inhibi- tion of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. Immunol (1995) 154:326–334.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN G, BOYLE D, BULLOUGH D et al.: Protectiveeffect of an adenosine kinase inhibitor in septic shock. Immunol (1994) 152:5853–5859.
   Web of Science ®Google Scholar
• COTTAM HB, WASSON DB, SHIH HC, RAYCHAUDHURI A,DIPASQUALE G, CARSON DA: New adenosine kinase inhibitors with oral antiflammatory activity: synthesis and biological evaluation. J. Med. Chem. (1993) 36:3424–3430.
   PubMed Web of Science ®Google Scholar
• COWART MC, BENNETT M, GFESSER G et al.: SAR of aseries of nucleoside analogues as adenosine kinase inhibitors. 213th ACS National Meeting, San Francisco, USA. (April 13–17 1997) Medi 173.
   Google Scholar
• KOWALUK EA, BHAGWAT SS, JARVIS MF: Adenosine kinase inhibitors. Curr. Pharmaceut. Design (1998) 4:403–416.
   PubMed Web of Science ®Google Scholar
• SANTICIOLI P, DEL BIANCO E, TRAMONTANA M, MAGGICA: Adenosine inhibits action potential-dependent release of calcitonin gene-related peptide- and substance P-like immunoreactivities from primary afferents in rat spinal cord. Neurosci. Lett. (1992) 144:211–214.
   PubMed Web of Science ®Google Scholar
• SALTER MW, De KONINCK Y, HENRY JL: Physiologicalroles of adenosine and ATP in synaptic transmission in the spinal dorsal horn. Prog. Neurobiol. (1993) 41:125–156.
   PubMed Web of Science ®Google Scholar
• LIE, PER L: Adenosine inhibition of synaptic transmis-sion in the substantia gelatinosa. J. Neurophysiol (1994) 4:1611–1621.
   Google Scholar
• SAWYNOK J, SWEENEY MI, WHITE TD: Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br. J. Pharmacol (1986) 88:923–930.
   PubMed Web of Science ®Google Scholar
• REEVE AJ, DICKENSON AH: The roles of spinal adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurones in the anaesthetized rat. Br. J. Pharmacol. (1995) 116:2221–2228.
   PubMed Web of Science ®Google Scholar
• HERRICK-DAVIS K, CHIPPARI S, LUTTINGER D, WARD SJ: Evaluation of adenosine agonists as potential analge-sics. Eur. j Pharmacol. (1989) 162:365–369.
   PubMed Web of Science ®Google Scholar
• YARBROUGH GG, McGUFFIN-CLINESCHMIDT JC: In vivo behavioral assessment of central nervous system purinergic receptors. Eur. J. Pharmacol. (1981) 76:137–144.
   PubMed Web of Science ®Google Scholar
• DOAK GJ, SAWYNOK J: Complex role of peripheraladenosine in the genesis of the response to subcutaneous formalin in the rat. Eur. J. Pharmacol (1995) 281:311–318.
   PubMed Web of Science ®Google Scholar
• SAWYNOK J, REID A, POON A: Peripheral antinocicep-tive effect of an adenosine kinase inhibitor with augmentation by an adenosine deaminase inhibitor, in the rat formalin test. Pain (1998) 74:75–81.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB, DUNWIDDIE TV: How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. (1988) 9:130–134.
   Google Scholar
• KOWALUK EA: Adenosine modulation: a novel approach to analgesia and inflammation. Exp. Opin. Invest. Drugs (1998) 7:535–543.
   PubMedGoogle Scholar
• HOLMGREN M, HEDNER J, MELLSTRAND T, NORDBERGG, HEDNER T: Characterization of the antinociceptive effects of some adenosine analogues in the rat. Naunyn-Schmiedeberg's Arch Pharmacol. (1986) 334:290–293.
   Google Scholar
• KEIL GJ, DELANDER GE: Spinally mediated antinocicep-tion is induced in mice by an adenosine kinase, but not an adenosine deaminase inhibitor. Life Sci. (1992) 51:171–176.
   Google Scholar
• •First report of the antinociceptive effects of an AK inhibitor.
   Google Scholar
• POON A, SAWYNOK J: Antinociception by adenosineanalogues and an adenosine kinase inhibitor: depend-ence on formalin concentration. Eur. J. Pharmacol (1995) 286:177–184.
   PubMed Web of Science ®Google Scholar
• AHLIJANIAN MK, TAKEMORI AE: Effects of 0-N6-(R-phenylisopropyfiadenosine and caffeine on nociception and morphine-induced analgesia, tolerance and dependence. Eur. J. Pharmacol. (1985) 112:171–179.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, YAKSH TL: Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Pain (1992) 49:121–128.
   PubMed Web of Science ®Google Scholar
• LAVAND'HOMME PM, EISENACH JC: Exogenous and endogenous adenosine enhance the spinal antiallo-dynic effects of morphine in a rat model of neuropathic pain. Pain (1999) 80:31–36.
   PubMed Web of Science ®Google Scholar
• SOLLEVI A: Adenosine for pain control. Acta Anesth. Scand (1997) 110:135–136.
   Google Scholar
• SEGERDAHL M, IRESTEDT L, SOLLEVI A: Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Acta Anesth. Scand. (1997) 41:180–185.
   Web of Science ®Google Scholar
• KARLSTEN R, GORDH T: An Ai-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg. (1995) 80:844–847.
   PubMed Web of Science ®Google Scholar
• •Clinical case report of the effects of an A1 receptor agonist in human neuropathic pain.
   Google Scholar
• KOWALUK EA, KOHLHAAS K, BANNON A, GUNTHER K, LYNCH JJ, JARVIS MF: Characterization of the effects of adenosine kinase inhibitors on acute thermal nocicep-tion in mice. Pharmacol. Biochem. Behav. (1999) 63:83–91.
   PubMed Web of Science ®Google Scholar
• POON A, SAWYNOK J Antinociception by adenosine analogues and inhibition of adenosine metabolism in © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3) an inflammatory thermal hyperalgesia model in the rat. Pain (1998) 74: 235–245.
   Google Scholar
• KOWALUK EA, MIKUSA J, WISMER C, JARVIS MF: An adenosine kinase inhibitor attenuates carrageenan-induced hyperalgesia and inflammation in the rat. Drug Dev. Res. (1998) 43:39.
   Google Scholar
• LYNCH JJ, JARVIS MF, KOWALUK EA: An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain. Eur. J. Pharmacol (1999) 364:141–146.
   PubMed Web of Science ®Google Scholar
• WANG B, RANG J, WHITE PF et al.: The effect of GP683,an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth. Analg. (1997) 85:675–680.
   PubMed Web of Science ®Google Scholar
• ERION MD, WIESNER JB, DARE J, KOPCHO J, UGARKARBG: Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleo-sides Nucleotides (1997) 16:1013–1021.
   Web of Science ®Google Scholar
• CRONSTEIN BN, NAIME ED, FIRESTEIN G: The anti-inflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arth. Rheum. (1995) 38:1040–1045.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS: Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev. Res. (1996) 39:371–376.
   Web of Science ®Google Scholar
• •Overview of the anti-inflammatory properties of adenosine and adenosine kinase inhibitors. First report of the effects of AK inhibitor in rat adjuvant arthritis model.
   Google Scholar
• BONG GW, ROSENGREN S, FIRESTEIN GS: Spinal cord adenosine receptor stimulation in rats inhibits dermal neutrophil accumulation: the role of N-methyl-D- aspartate receptors. J. Clin. Invest. (1996) 98:1–7.
   PubMed Web of Science ®Google Scholar
• ROSENGREN S, BONG GW, FIRESTEIN GS: Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J. Immunol. (1995) 154:5444–5451.
   PubMed Web of Science ®Google Scholar
• WINN HR, WELSH JE, RUBIO GR, BERNE RM: Changes in brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ. Res. (1980) 47:568–577.
   Google Scholar
• MILLER LP, HSU C: Therapeutic potential for adenosine receptor activation in ischemic brain injury. J. Neurotrauma (1992) 9:S563–S577.
   PubMed Web of Science ®Google Scholar
• ONODERA H, SATO G, KOGURE K: Quantitative autora-diographic analysis of muscarinic, cholinergic and adenosine Ai binding sites after transient forebrain ischemia in the gerbil. Brain Res. (1987) 415:309–322.
   PubMed Web of Science ®Google Scholar
• EVANS MC, SWAN JH, MELDRUM BS: An adenosine analogue, 2-chloroadenosine, protects against long term development of ischemic cell loss in the rat hippocampus. Neurosci. Lett. (1987) 83:287–292.
   PubMed Web of Science ®Google Scholar
• VON LUBITZ DKJE: Adenosine and acute treatment ofcerebral ischemia and stroke-'put out more flags'. In: Purinergic Approaches in Experimental Therapeutics. Jacobson KA, Jarvis MF, (Eds.) Wiley-Liss, New York, USA (1997) 449–470.
   Google Scholar
• GOLDBERG MP, MONYER H, WEISS HH, CHOI DW: Adenosine reduces cortical neuronal injury induced by oxygen and glucose deprivation in vitro. Neurosci. Lett. (1988) 89:323–327.
   PubMed Web of Science ®Google Scholar
• LYNCH JJ, ALEXANDER K, JARVIS MF, KOWALUK EA: Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. Neurosci. Lett. (1998) 252: 207–210.
   PubMed Web of Science ®Google Scholar
• SIMON RP, SWAN JH, GRIFFITHS T, MELDRUM BS: Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science (1984) 226:850–852.
   PubMed Web of Science ®Google Scholar
• FOSTER AC, FAGG GE: Neurobiology. Taking apart NMDA receptors. Nature (1987) 329:395–396.
   Google Scholar
• CRAIG GG, WHITE TD: N-methyl-D-aspartate and non-methyl-D-aspartate-evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J. Neurochem. (1993) 60:1073–1080.
   PubMed Web of Science ®Google Scholar
• WHITE TD: Potentiation of excitatory aminoacid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. Eur. J. Pharmacol (1996) 303:27–38.
   PubMed Web of Science ®Google Scholar
• HOSLI L, HOSLI E, UHR M, DELLA BRIOTTA G: Electro-physiological evidence for adenosine receptors on astrocytes of cultured rat central nervous system. Neurosci. Lett. (1987) 79:108–112.
   PubMed Web of Science ®Google Scholar
• PHILLIS JW, SMITH-BARBOUR M: The adenosine kinaseinhibitor, 5-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sci. (1993) 53:497–502.
   PubMed Web of Science ®Google Scholar
• MILLER LP, JELOVICH LA, YAO L, DARAE J, UGARKAR B,FOSTER AC: Pre- and pen- stroke treatment with the adenosine kinase inhibitor, 5'deoxylodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci. Lett. (1996) 220:73–76.
   PubMed Web of Science ®Google Scholar
• •First demonstration that a systemically administered AK inhibitor reduces transient ischaemia-induced infarct size in vivo.
   Google Scholar
• JIANG N, KOWALUK EA, LEE C-H, MAZDIYASNI H, CHOPPM: Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Eur. J. Pharmacol (1997) 320:131–137.
   PubMed Web of Science ®Google Scholar
• KOWALUK EA, KOHLHAAS KL, ZHU C et al: A-134974, anovel adenosine kinase inhibitor with neuroprotec-tive properties. Pharmacologist (1997) 39:341.
   Google Scholar
• TATLISUMAK T, TAKANO K, CARANO RAD, MILLER LP,FOSTER AC, FISHER M: Delayed treatment with an adenosine kinase inhibitor, GP 683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke (1998) 29: 1952-1958.
   Google Scholar
• BERNE RM, KNABB RM, ELY SW, RUBIO R: Adenosine inthe local regulation of blood flow: a brief review. Fed. Proc. (1983) 42:3136-3142. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• MAITRE M, CIESIELSKI L, LEHMAN A, KEMPF E, MANDELP: Protective effect of adenosine and nicotinamide against audiogenic seizure. Biochem. Pharmacol (1974) 23:2807.
   PubMed Web of Science ®Google Scholar
• DRAGUNOW M, GODDARD GV, LAVERTY R: Is adenosine an endogenous anticonvulsant? Epilepsia (1985) 26:480–487.
   PubMed Web of Science ®Google Scholar
• KNUTSEN US, MURRAY TF: Adenosine and ATP in epilepsy. In: Purinergic Approaches in Experimental Therapeutics. Jacobson KA, Jarvis MF, (Eds.) Wiley-Liss, New York, USA (1997):423–424.
   Google Scholar
• BERMAN RF, JARVIS MF, LUPICA CR: Adenosine involve-ment in kindled seizures. Kindling (1990) 4:423–440.
   Google Scholar
• DURING MJ, SPENCER DD: Adenosine: a potentialmediator of seizure arrest and postictal refractoriness. Ann. Neurol (1992) 32:618–624.
   PubMed Web of Science ®Google Scholar
• •Demonstration that ADO concentrations are increased following an epileptic seizure in humans.
   Google Scholar
• KLEINSORGE RJ, BOWERS LM, JARVIS MF, BERMAN RF:Chronic theophylline prolongs the refractory period in amygdala-kindled rats. Drug Dev. Res. (1993) 29:287–291.
   Web of Science ®Google Scholar
• ZHANG G, FRANKLIN PH, MURRAY TF: Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol Exp. Ther. (1993) 264:1415–1424.
   PubMed Web of Science ®Google Scholar
• •Demonstration that an AK inhibitor is more effective than an ADA inhibitor in an in vivo model of seizure activity.
   Google Scholar
• KOWALUK EA, KOHLHAAS KL, DAANEN J, LEE CH: Anticonvulsant effects of adenosine kinase inhibitors. Drug Dev. Res. (1996) 37:190.
   Google Scholar
• BERMAN RF, CORTESE B, WIESNER JB: Anticonvulsant activity of an adenosine kinase inhibitor, GP 3269 against amygdala-kindled seizures in rats. Soc. Neurosci. Abstr. (1997) 23:840–843.
   Google Scholar
• WIESNER JB, UGARKAR BG, CASTELLINO AJ et al.: Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J. Pharmacol. Exp. Ther. (1999) 289:1669–1677.
   PubMed Web of Science ®Google Scholar